trial

Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder

NCTId NCT06939088
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Recruiting
Enrollment 108 (estimated)
Sponsored by Anders Fink-Jensen, MD, DMSci
Primary completion 2028-08-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Recruiting
Enrollment
108 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2025-05-05
Primary completion
2028-08-01
Eligibility
ALL · 18 Years · 70 Years

Interventions & indications

Drugs
Tirzepatide

Sponsors

Anders Fink-Jensen, MD, DMSciLead Sponsor

Investigators

1
Anders Fink-Jensen, MD, DMSc, ProfessorPrincipal Investigator

Sites

2 total
Aalborg, DenmarkFrederiksberg, Denmark

Linked catalysts

1
Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophreni — primary completion2028-08-01

Facts & assertions

4 sourced
Enrollment
108
Phase
PHASE2
Primary Completion Date
2028-08-01
Status
RECRUITING
relationships
The graph out of here
drug
Tirzepatide
drug
lead_sponsor
Anders Fink-Jensen, MD, DMSci
company
indication
Schizophrenia Spectrum and Other Psychotic Disorders
indication
Alcohol Abuse/Dependence
indication
Alcohol Dependence
indication
investigator
Anders Fink-Jensen, MD, DMSc, Professor
person